Table 3

Comparison of predictions of the three-state model with experimental data

Agonist	pEC₅₀		E_maxagonist/E_max 5-HT		L = M = 100
	IP		AA		IP		AA		K_A	K_A*	K_A**
	Actual	Model	Actual	Model	Actual	Model	Actual	Model	K_A	K_A*	K_A**
5-HT	7.43	7.39	7.34	7.39	1.00	1.00	1.00	1.00	1.00E-05	8.00E-10	8.00E-10
bufotenin	6.50	6.39	6.33	6.39	0.78	0.79	1.08	1.13	1.00E-05	1.00E-08	7.00E-09
DOI	6.72	6.76	6.80	6.76	0.61	0.61	0.97	0.96	8.00E-07	5.60E-09	3.60E-09
LSD	7.80	8.09	8.11	8.09	0.17	0.16	0.39	0.40	1.10E-08	1.00E-09	4.00E-10
quipazine	5.89	6.04	6.06	6.04	0.89	0.89	0.59	0.60	3.50E-06	2.00E-08	3.00E-08
TFMPP	6.34	6.43	6.48	6.43	1.02	1.03	0.59	0.60	2.00E-06	7.00E-09	1.20E-08

Computer simulations with the three-state model were done as described in the text. “Actual” data are from experiments with 5-HT_2Creceptor-mediated IP accumulation and AA release (Fig. 4 and Table 1). The values obtained from computer simulations (model) closely approximate the experimental data (actual).